Biliary Atresia: The Silent Obstruction Behind Neonatal Jaundice

Mahnoor Azhar

1st Year BDS, Islamabad Medical and Dental College, Islamabad, Pakistan

Key points:

- Biliary atresia is a progressive, fibro-inflammatory obliteration of the extrahepatic biliary tree, presenting as neonatal cholestasis.
- Characterized by persistent jaundice extending past the neonatal period, acholic (pale/clay-colored) stools, dark urine, and hepatomegaly.
- Diagnosed via a combination of biochemical markers, ultrasonography, and confirmed via intraoperative cholangiography or liver biopsy.
- Requires urgent intervention with the Kasai portoenterostomy, which yields significantly better prognoses if performed within the first 60 days of life.
- Despite early surgical management, many patients experience progressive hepatic fibrosis, making biliary atresia the leading indication for pediatric liver transplantation.

Introduction

A newborn's first cry marks the beginning of life but for some infants, an invisible process has already begun long before birth. Biliary atresia is not merely a disease; it is a progressive destruction of the biliary system that silently compromises liver function within weeks of life. Characterized by fibro-inflammatory obliteration of the extrahepatic bile ducts, BA leads to cholestasis, liver fibrosis, and ultimately cirrhosis if untreated.

Despite decades of research, the true cause of biliary atresia remains elusive. What makes this disease particularly devastating is not just its severity, but its complex and multifactorial origin involving immune dysregulation, environmental toxins, and possibly even maternal influences during pregnancy.[3]

Clinically, the disease presents a diagnostic dilemma. Early manifestations, prolonged jaundice, pale stools, and dark urine often overlap with more benign conditions or other hepatobiliary anomalies such as choledochal cysts. This overlap can delay diagnosis at a time when intervention is most critical. The timing of surgical management, particularly the Kasai portoenterostomy, is a decisive factor in determining prognosis, with outcomes significantly improved when performed within the first 60 days of life. Thus, biliary atresia is not only a disease of biological complexity but also one of clinical urgency, where each passing day contributes to disease progression.[1]

Clinical Features

Clinically, biliary atresia typically presents within the first few weeks of life. The most characteristic feature is persistent jaundice that extends beyond the neonatal period. Parents often notice pale or clay coloured stools, which reflect the absence of bile pigments in the intestine, along with dark urine due to increased

conjugated bilirubin excretion through the kidneys. On examination, the infant may have hepatomegaly due to bile retention and ongoing hepatic inflammation. As the disease progresses, signs of chronic liver disease become evident, including poor weight gain, irritability, and abdominal distension. In later stages, complications such as splenomegaly and ascites develop as a result of portal hypertension, indicating advanced hepatic fibrosis.[4]

Diagnosis

The diagnosis of biliary atresia requires a combination of clinical suspicion and supportive investigations. Laboratory findings typically show conjugated hyperbilirubinemia, elevated gamma-glutamyl transferase (GGT), and mildly increased transaminases, consistent with cholestatic liver injury.[4]

Ultrasonography is often the first imaging modality used and may reveal an absent or small gallbladder, as well as the triangular cord sign, which represents fibrotic remnants of the obliterated extrahepatic bile duct.1 Hepatobiliary scintigraphy (HIDA scan) is a key diagnostic tool in evaluating neonatal cholestasis. In biliary atresia, the HIDA scan shows normal hepatic uptake of the radiotracer but absence of excretion even after delayed imaging, indicating complete biliary obstruction.[4]

Liver biopsy provides further diagnostic confirmation by demonstrating bile duct proliferation, portal tract fibrosis, and bile plugs within canaliculi. Ultimately, intraoperative cholangiography remains the gold standard for definitive diagnosis, as it directly visualizes the absence or obliteration of the extrahepatic biliary tree.[1]

Management

The mainstay of treatment for biliary atresia is the Kasai portoenterostomy, a surgical procedure in which the fibrotic extrahepatic bile ducts are excised and a Roux-en-Y jejunal loop is anastomosed directly to the liver hilum to restore bile drainage. The success of this procedure is highly dependent on early intervention, ideally before 60 days of age.[5]

Medical management is supportive and includes nutritional optimization with high-calorie feeds and supplementation of fat-soluble vitamins (A, D, E, and K), as cholestasis significantly impairs their absorption. Antibiotics are used to prevent or treat episodes of ascending cholangitis, a common complication following surgery.

Despite early surgical intervention, many patients eventually progress to end-stage liver disease and require liver transplantation, which remains the definitive treatment for advanced biliary atresia.[2]

Prognosis

The prognosis of biliary atresia is strongly dependent on the age at surgery and the extent of hepatic fibrosis at diagnosis. Early Kasai portoenterostomy significantly improves bile drainage and delays disease progression. However, even with successful surgery, a substantial proportion of patients eventually develop cirrhosis and require liver transplantation. Without treatment, biliary atresia is uniformly fatal within the first few years of life due to progressive liver failure.[6]

Conclusion

Biliary atresia is a devastating disease affecting newborns, and there is thus a dire need for therapy development. There is considerable progress on several fronts, ranging from recent insights into the underlying pathomechanisms to direct small-scale clinical trials using immunomodulatory therapies. There is also progress in advancing BA diagnosis which is important to better stratify patients, in particular to decide if and when liver transplants are required. Innovative research using different model systems including organoids, is also likely to further accelerate the discovery process for new pharmacological intervention principles and cell therapy approaches. There is thus reason to be cautiously optimistic that in a not-too-distant future, we

will be able to develop therapies to ameliorate, or even cure, biliary atresia, for the benefit of the patients.[3]

References

1. Hartley JL, Davenport M, Kelly DA. Biliary atresia. The Lancet. 2009;374(9702):1704–1713.
2. Mack CL, Sokol RJ. Biliary atresia: pathogenesis and management. Journal of Clinical Gastroenterology. 2005;39(4):S174–S181.
3. Bezerra JA, Wells RG, Mack CL, et al. Biliary atresia: clinical and research challenges. Hepatology. 2018;68(3):1163–1173.
4. Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants. Journal of Pediatric Gastroenterology and Nutrition. 2017;64(1):154–168.
5. Kasai M. Treatment of biliary atresia with special reference to hepatic portoenterostomy. 1959.
6. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia. Liver Transplantation. 2007;13(11):1487–1493.